Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET
Author:
Publisher
Springer International Publishing
Link
http://link.springer.com/content/pdf/10.1007/978-3-319-91442-8_13
Reference30 articles.
1. Boss DS et al (2012) A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 106(10):1598–1604. ISSN 1532-1827. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/22516948
2. Bruheim S et al (2011) Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts. Int J Cancer 129(3):742–750. ISSN 1097-0215. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/21225632
3. Cabanillas ME et al (2015) A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer 121(16):2749–2756. ISSN 1097-0142. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/25913680
4. Finn RS, Cheng A-L, Ikeda K et al (2017) A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma. ASCO
5. Flaherty KT et al (2015) BEST: a randomized phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma—a trial of the ECOG-ACRIN Cancer Research Group (E2804). J Clin Oncol 33(21):2384–2391. ISSN 1527-7755. Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/26077237
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Design and Synthesis of Novel Thieno[3,2-c]quinoline Compounds with Antiproliferative Activity on RET-Dependent Medullary Thyroid Cancer Cells;ACS Omega;2023-09-11
2. Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications;MedComm;2023-05-02
3. Evaluation and Prediction of Treatment Response for Hepatocellular Carcinoma;Magnetic Resonance in Medical Sciences;2023
4. The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma;Hepatology Research;2022-11-06
5. Comprehensive analysis of complement-associated molecular features in hepatocellular carcinoma;Acta Biochimica et Biophysica Sinica;2022-08-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3